Category Archives: Immunology

Immunology

Society for Immunotherapy of Cancer Forward Fund Announces Recipients of Cancer Immunotherapy Fellowships and Technology Awards – PR Web

Society for Immunotherapy of Cancer (SITC)

MILWAUKEE (PRWEB) August 12, 2022

The Society for Immunotherapy of Cancer (SITC) Forward Fund is pleased to announce the recipients of the 2022 Fellowships and Technology Awards, which support the next generation of cancer immunotherapy and tumor immunology experts through dedicated funding of novel research.

Together with the immense generosity of our supporters, SITC is honored to help young investigators realize their cancer immunotherapy research dreams, said SITC President Patrick Hwu, MD. It is our hope that these young researchers turn their dreams and cure into a reality for all cancer patients.

These awards are financially supported through the Forward Fund, which was established by SITC in 2012 to stimulate the future of science, development and application of cancer immunology and immunotherapy through financially supporting its education and research. Since 2014, SITC has awarded more than $5 million in funding to deserving early career scientists in the field of cancer immunotherapy.

The 2022 SITC Fellowship and Technology Award recipients are:

SITC-Bristol Myers Squibb Postdoctoral Cancer Immunotherapy Translational FellowshipAward Amount: $200,000 (two-year)Awardee: Simone Minnie, PhDInstitution: Fred Hutchinson Cancer Research Center Project Title: Harnessing Treg fragility to improve anti-myeloma immune responses

SITC-Amgen Cancer Immunotherapy in Hematologic Malignancies FellowshipAward Amount: $100,000 (one-year)Awardee: John Ligon, MDInstitution: University of FloridaProject Title: Leveraging CD70 CXCR2-modified CAR T-cells for treating AML

SITC-AstraZeneca Immunotherapy in Lung Cancer Clinical FellowshipAward Amount: $100,000 (one-year)Awardee: Jonathan Chen, MD, PhDInstitution: Massachusetts General HospitalProject Title: Dissecting the tumor immunity multicellular network

SITC-Merck Cancer Immunotherapy Clinical FellowshipAward Amount: $100,000 (one-year)Awardee: Hitomi Hosoya, MD, PhDInstitution: Stanford UniversityProject Title: Cell-free DNA-based Platform to Determine Treatment Response and Resistant Mechanisms to CAR T-cell Therapy in Multiple Myeloma

SITC-Genentech Women in Cancer Immunotherapy FellowshipAward Amount: $50,000 (one-year)Awardee: Shu-chin Lai, PhDInstitution: Huntsman Cancer Institute, University of UtahProject Title: Augmenting T cell immunity to facilitate metastatic breast cancer treatment

SITC-Nektar Therapeutics Equity and Inclusion in Cancer Immunotherapy FellowshipAward Amount: $50,000 (one-year)Awardee: Mara De Martino, PhDInstitution: Weill Cornell MedicineProject Title: Targeting FASN to sensitize irradiated glioblastoma to immunotherapy

SITC-Mallinckrodt Pharmaceuticals Adverse Events in Cancer Immunotherapy Clinical FellowshipAward Amount: $40,000 (one-year)Awardee: Steven Blum, MDInstitution: Dana-Farber Cancer Institute, Massachusetts General HospitalProject Title: Distinguishing Immune-Related Adverse Events (irAEs) from Anti-Tumor Immunity

SITC-Natera ctDNA in Immunotherapy Response Monitoring Fellowship and Technology AwardAward: $40,000 and access to Nateras Signatera testing technology Awardee: Mariya Rozenblit, MDInstitution: Yale UniversityProject Title: The tumor microenvironment of triple negative breast cancers with detectable circulating tumor DNA after pembrolizumab treatment

SITC-NanoString Technologies Single Cell Biology AwardAward: Access to NanoString Technologies CosMx Spatial Molecular Imager (SMI)Awardee: Elshad Hasanov, MD, PhDInstitution: University of Texas MD Anderson Cancer CenterProject Title: CosMxing renal cell carcinoma brain metastases to decipher immune checkpoint inhibitor resistance mechanisms at single-cell and spatial context

This years SITC Forward Fund Fellowships and Technology Awards were made possible through the generosity of Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, Mallinckrodt Pharmaceuticals, Merck, Nektar Therapeutics, NanoString Technologies and Natera Technologies. The fellowship and technology award recipients will be honored during a ceremony at the societys 37th Annual Meeting at the Boston Convention and Exhibition Center in Boston, Massachusetts.

To learn more about current and past SITC Fellowship and Technology Award recipients, visit SITCs website.

About SITCEstablished in 1984, the Society for Immunotherapy of Cancer (SITC) is a nonprofit organization of medical professionals dedicated to improving cancer patient outcomes by advancing the development, science and application of cancer immunotherapy and tumor immunology. SITC is comprised of influential basic and translational scientists, practitioners, health care professionals, government leaders and industry professionals around the globe. Through educational initiatives that foster scientific exchange and collaboration among leaders in the field, SITC aims to one day make the word cure a reality for cancer patients everywhere. Learn more about SITC, our educational offerings and other resources at sitcancer.org and follow us on Twitter, LinkedIn, Facebook and YouTube.

Share article on social media or email:

View original post here:
Society for Immunotherapy of Cancer Forward Fund Announces Recipients of Cancer Immunotherapy Fellowships and Technology Awards - PR Web

Immunology

Chemomab Adds Highly Experienced Executives Further Strengthening Its R&D and Clinical Capabilities – Yahoo Finance

Appoints Ilan Vaknin, PhD, as Vice President of Research & Development and Christina Crater, MD, as Vice President of Clinical Development

TEL AVIV, Israel, Aug. 12, 2022 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced the addition of Ilan Vaknin, PhD, MBA, as Vice President of Research & Development and Christina Crater, MD, as Vice President of Clinical Development.

Chemomab logo (PRNewsfoto/Chemomab Therapeutics, Ltd.)

"Chemomab is distinguished by the strength of its science, and we are fortunate these two premiere scientific and medical professionals are assuming critical roles as we progress the development of CM-101, our pipeline in a product with breakthrough potential," said Dale Pfost, PhD, Chief Executive Officer of Chemomab. "We are preparing to report topline results from our Phase 2 trial in liver fibrosis patients later this year, we are expanding our Phase 2 trial of CM-101 in primary sclerosing cholangitis, we will soon be launching a Phase 2 biological proof of concept trial in systemic sclerosis, and we are assessing potential new indications for CM-101 in other fibro-inflammatory disorders. Dr. Vaknin's more than 20 years of broad-ranging experience in immunology, bioassay development, and antibody R&D and manufacturing will be invaluable as we work to accelerate advancement of our pipeline programs."

Dr. Vaknin brings Chemomab more than two decades of biotechnology drug discovery and development experience in immunology, antibody development, translational research and bioassay development, including more than a decade in senior science roles at Compugen, Ltd. He most recently served as Director of Preclinical Bioassays, where he oversaw preclinical bioassay development and related activities, while working with computational and validation teams to support discovery of novel drug targets and biomarkers. Prior to Compugen, Dr. Vaknin served as Chief Technology Officer at Active P, where he led the development of orally available therapeutic peptides. Earlier in his career, he served as External Scientific Consultant for the Department of Neurobiology at Israel's Weizmann Institute of Science. Dr. Vaknin holds a PhD in immunology and a BA in life sciences from The Hebrew University of Jerusalem, where he also received an MBA in finance.

Story continues

Dr. Pfost continued, "Dr. Crater's extensive background in medical affairs and clinical trial design and execution across a broad range of therapeutic indications will be instrumental as we ramp up our clinical activities. She has highly relevant experience leading clinical research programs in immuno-inflammation and orphan diseases. Her decade as a front-line physician gives her a first-hand appreciation for the essential roles of patients and physicians in the successful development of new therapies. I am delighted to welcome Ilan and Chris to the Chemomab senior team at this exciting time in our evolution."

Dr. Crater has served as a medical monitor, safety physician, therapeutic expert and study director in all phases of clinical development, including extensive experience in data quality and safety monitoring. Her career spans working in-house at pharmaceutical and biotechnology firms, as well as at major clinical research organizations (CROs). Previously Dr. Crater served as Senior Clinical Trial Physician at Bristol-Myers Squibb, where she was responsible for the review and interpretation of clinical data while contributing to strategic decisions on clinical study design and asset advancement. Dr. Crater also served in senior clinical development roles with PRA Health Sciences and PAREXEL International. Earlier in her career, Dr. Crater worked as an internal medicine physician. She received an MD degree from the University of Tennessee and holds a BS from Rhodes College. Dr. Crater is board certified in Internal Medicine.

About Chemomab Therapeutics

Chemomabis a clinical-stage biotechnology company focusing on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need. Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to bind and block CCL24 activity. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is currently in Phase 2 trials for primary sclerosing cholangitis and liver fibrosis, with a Phase 2 trial in systemic sclerosis expected to begin in late 2022. For more information, visitchemomab.com.

Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These forward-looking statements include, among other things, statements regarding the clinical development pathway for CM-101; the future operations of Chemomab and its ability to successfully initiate and complete clinical trials and achieve regulatory milestones; the nature, strategy and focus of Chemomab; the development and commercial potential and potential benefits of any product candidates of Chemomab; and that the product candidates have the potential to address high unmet needs of patients with serious fibrosis-related diseases and conditions. Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based upon Chemomab's current expectations. Forward-looking statements involve risks and uncertainties. Because such statements deal with future events and are based on Chemomab's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Chemomab could differ materially from those described in or implied by the statements in this presentation, including: risks related to Chemomab's ability to effectively implement the revised clinical strategy and its ability to achieve the anticipated results; risks related to the projections and associated benefits in pursuing the contemplated changes to the clinical strategy; risks associated with the ongoing transitions of certain of our executive officers; the uncertain and time-consuming regulatory approval process; risks related to Chemomab's ability to correctly manage its operating expenses and its expenses; Chemomab's plans to develop and commercialize its product candidates, focusing on CM-101; the timing of initiation of Chemomab's planned clinical trials; the timing of the availability of data from Chemomab's clinical trials including any potential delays associated with Chemomab's contemplated revised clinical strategy; the timing of any planned investigational new drug application or new drug application; Chemomab's plans to research, develop and commercialize its current and future product candidates; the clinical utility, potential benefits and market acceptance of Chemomab's product candidates; Chemomab's commercialization, marketing and manufacturing capabilities and strategy; Chemomab's ability to protect its intellectual property position; and the requirement for additional capital to continue to advance these product candidates, which may not be available on favorable terms or at all. Additional risks and uncertainties relating to Chemomab's and its business can be found under the caption "Risk Factors" and elsewhere in Chemomab's filings and reports with the SEC. Chemomab expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Chemomab's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based, except to the extent required by applicable law.

Contacts:

Media:

Investor Relations:

Barbara Lindheim

Irina Koffler

Chemomab Therapeutics

LifeSci Advisors, LLC

Consulting Vice President

Phone: +1-917-734-7387

Investor & Public Relations,

ir@chemomab.com

Strategic Communications

Phone: +1-917-355-9234

barbara@chemomab.com

Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/chemomab-adds-highly-experienced-executives-further-strengthening-its-rd-and-clinical-capabilities-301604869.html

SOURCE Chemomab Therapeutics, Ltd.

See original here:
Chemomab Adds Highly Experienced Executives Further Strengthening Its R&D and Clinical Capabilities - Yahoo Finance

Immunology

Professor Dr.Tzenios was inducted into the hall of Fame of the Medical Research Council (FMRC) USA by honoring him with a distinguished FMRC…

Professor Dr. Nikolaos Tzenios,Ph.D., FRSPH, FRSM, FAAMFM, FWAMS, FMRC, AcIASS, mRSB, DABAAHP|, a University Professor of Public Health,had been inducted into the hall of fame by honoring him with theFellowship of theMedical Research Council (FMRC) for hisremarkable contribution to medical research. His international journal publications have received international acclaim and significantly impacted the global research community.

This is to certify that renowned researcher Professor Dr.Nikolaos Tzenios is hereby recognized and honored as aFellow of Medical Research Council (FMRC).The designated fellow is elected to the esteemed grade for theexceptional achievements in pursuit of advanced studies &research in his work and remarkable contributions to CancerResearch.Dr. Vivek Dubey, (MS, Ph.D., University of Wisconsin)Secretary Open Association of Research Society, Delaware.

Professor Dr. Nikolaos Tzenios research articles with several citations show his profound understanding of research methodology and display his keen insight into the subtle aspects of his field. They were selected for publication after passing through the exhaustive peer-review parameters and approved by an editorial board comprising eminent researchers and scientists.

Dr. Nikolaos Tzenios shows the originality of thought and delves into hitherto untouched areas.

TheFellowship of theMedical Research CouncilIt is not only an award but also a membership granted to individuals which the Open Association of Research Society Judges feel that the Scientist has made a substantial contribution to the improvement of Cancer Research.

The designated Fellows are the most eminent scientists, engineers, and technologists worldwide. The credentials of Fellow designation signify that the researcher has gained knowledge of fundamental and high-level concepts, is a subject matter expert, is proficient in an expertise course covering the professional code of conduct and follows recognized standards of practice.

Professor Tzenios communicates his ideas with spontaneous ease and shows academic commitment and research aptitude, which give us enough ground to believe that he has the potential to render yeomanly services in the academic field. This gives us enough ground to believe his knowledge will benefit the upcoming research scholars.

Almost all the leading indexing organizations have indexed Global Journals Organisation journals. It publishes journals in forty disciplines bringing out around three hundred research articles per month read by about two hundred thousand readers in different parts of the world. Research contribution comes from renowned researchers and scientists from universities of one hundred fifty-seven countries. The organization has to its credit the publication of more than eighteen thousand research works.

Dr. Nikolaos Tzenios the Senior Executive Vice-President of the World Academy of Medical (https://www.linkedin.com/in/nicolastzenios) is a member of the Scientific board of the European Medical Association, a Fellow of The Royal Society for Public Health (UK), a Fellow of The Royal Society of Medicine (UK), a Fellow of the World Academy of Medical Sciences, a Fellow of the American Academy of Anti-Aging Medicine.

Dr. Tzenios is also a Member of the American Academy of Regenerative Medicine, a Member The European Academy of Allergy and Clinical Immunology, a Member American Academy of Allergy, Asthma & Immunology (AAAAI), and Member the American Federation for Medical Research, a Member of the Royal Society of Biology (U.K.) and an ASSOCIATE ACADEMICIAN of the International Academy of Social Sciences.

Media ContactCompany Name: Release NewsContact Person: Andrew BraithwaiteEmail: Send EmailPhone: +44 (0) 161 818 6487Country: United StatesWebsite: https://release-news.com/

Original post:
Professor Dr.Tzenios was inducted into the hall of Fame of the Medical Research Council (FMRC) USA by honoring him with a distinguished FMRC...

Immunology

Serum Calprotectin Levels Linked to Subclinical Carotid Atherosclerosis in Patients With Psoriatic Arthritis – Rheumatology Network

In patients with psoriatic arthritis (PsA), serum calprotectin levels are associated with the presence of carotid plaques, according to a study published in Frontiers in Immunology.1

In PsA patients, serum calprotectin level was independently associated with the presence of carotid plaques, probably involving platelet and endothelial cells activation, Isaac Cheng, PhD, of The Chinese University of Hong Kong in Shatin, China, and colleagues, wrote. Moreover, subclinical carotid atherosclerosis was associated with the inflammatory burden (as reflected by the disease duration) in these patients.

While the association between PsA and increased cardiovascular (CV) disease risk is well established, only limited data is available on the underlying mechanisms.

This cross-sectional study included 78patients (52.6% male, mean age 52 years) with PsA but without CV disease. Calprotectin levels in serum were quantified and high-resolution ultrasound was used to determine carotid intima-media thickness and the presence of plaque.

Of the patients, 37.2% had carotid plaques. Serum calprotectin level was significantly higher in the group with carotid plaques compared with those without carotid plaques (721.3 ng/ml vs 564.6 ng/ml, P = 0.005). Serum calprotectin level correlated with PsA disease duration and mean carotid intima-media thickness.

Least absolute shrinkage and selection operator regression was performed to screen out 19 predictive variables including age, gender, traditional CV risk factors, medication use, clinical features and disease activity. Ln-calprotectin (OR: 3.38, 95% CI [1.37, 9.47]; P = 0.026) and PsA disease duration (1.09, 95% CI [1.01, 1.18]; P = 0.013) were statistically significant in predicting carotid plaque.

Investigators developed a nomogram for discriminating the presence of carotid plaque, which they said was an easy reference for clinical practice, with good accuracy, sensitivity and specificity (AUC 0.744, sensitivity 65%, specificity 79%). They concluded that serum calprotectin level may be a useful biomarker associated with a high inflammatory burden and the presence of subclinical carotid atherosclerosis in patients with PsA.

A limitation of the study was that most of the patients had low disease activity, thus the results may not be applicable to patients with moderate or high disease activity.

Reference:

Cheng IT, Meng H, Li M, et al. Serum Calprotectin Level Is Independently Associated With Carotid Plaque Presence in Patients With Psoriatic Arthritis.Front Med (Lausanne). 2022;9:932696. Published 2022 Jul 8. doi:10.3389/fmed.2022.932696

See the rest here:
Serum Calprotectin Levels Linked to Subclinical Carotid Atherosclerosis in Patients With Psoriatic Arthritis - Rheumatology Network

Immunology

Senior Lecturer, Bacteriology job with UNIVERSITY OF MELBOURNE | 304525 – Times Higher Education

Location:ParkvilleRole type:Full time; ContinuingFaculty:Faculty of Medicine, Dentistry and Health SciencesDepartment/School:Department of Microbiology and ImmunologySalary:Level C $135,032 $155,698 p.a. plus 17% super

The University of Melbourne would like to acknowledge and pay respect to the Traditional Owners of the lands upon which our campuses are situated, the Wurundjeri and Boon Wurrung Peoples, the Yorta Yorta Nation, and the Dja Dja Wurrung People. We acknowledge that the land on which we meet and learn was the place of age-old ceremonies, celebration, initiation, and renewal, and that the local Aboriginal Peoples have had and continue to have a unique role in the life of these lands.

About The Department of Microbiology & Immunology

TheDepartment of Microbiology & Immunologyis one of three departments within the School of Biomedical Sciences in the Faculty of Medicine, Dentistry, and Health Sciences and is also an integral component of the Peter Doherty Institute for Infection and Immunity (http://www.doherty.unimelb.edu.au).

It accommodates nearly 40 research laboratories which span areas including bacteriology, virology, immunology, pathology, and cancer biology, a team of dedicated teaching specialists, and the Microbiology Diagnostic Unit, a public health microbiology diagnostic laboratory.

About the Role

As part of the departments strategic plan to build and strengthen its bacteriology discipline, we are seeking to fill two teaching and research positions; in addition to the Senior Lecturer, applications for Associate Professor / Professor in Bacteriology will be opening soon.

Along with an independent research program, you will make a major contribution to teaching in the field of microbiology as well as the associated curriculum, policy development, and administrative tasks. This will include responsibilities in specific undergraduate subjects including course coordination and the planning, implementation, and delivery of teaching activities as well as assessment approaches.

Further responsibilities include:

Located within the Parkville precinct, you will have access to world-leading infrastructure at the Bio21 Institute, as well as the superior equipment and resources of the Peter Doherty Institute.

About You

This role is well positioned to form productive linkages with the numerous research and health centres that are collocated within the precinct and as such, you will utilise your strong interpersonal skills to collaborate within the Department, the Doherty Institute, and the wider University precinct.

You are a natural leader and have an established track record in bacteriology, with clear potential to build a prominent and productive research program that complements the Department and Institute strengths in infection and immunity. Applicants with research programs that use innovative approaches to study host-pathogen interactions are particularly encouraged to apply.

You will also have:

To ensure the University continues to provide a safe environment for everyone, this position requires the incumbent to hold a current and valid Working with Children Check.

About the University

The University of Melbourne is consistently ranked amongst the leading universities in the world. We are proud of our people, our commitment to research and teaching excellence, and our global engagement.

Benefits of Working with Us

In addition to having the opportunity to grow and be challenged, and to be part of a vibrant campus life, our people enjoy a range of rewarding benefits:

To find out more, visithttps://about.unimelb.edu.au/careers/staff-benefits.

Be Yourself

We value the unique backgrounds, experiences and contributions that each person brings to our community and encourage and celebrate diversity. First Nations people, those identifying as LGBTQIA+, females, people of all ages, with disabilities and culturally and linguistically diverse people are encouraged to apply. Our aim is to create a workforce that reflects the community in which we live.

Join Us!

If you feel this role is right for you, please submit your application including a brief cover letter, your resume and your responses against the selection criteria^ (found in the Position Description) for the role.

^For information to help you with compiling short statements to answer the selection criteria and competencies, please go tohttp://about.unimelb.edu.au/careers/selection-criteria

We are dedicated to ensuring barrier free and inclusive practices to recruit the most talented candidates. If you require any reasonable adjustments with the recruitment process, please contact us athr-talent@unimelb.edu.au.

Position Description:0039842_Senior Lecturer_Bacteriology_PD.pdf

Applications close:21 SEPT 2022 11:55 PMAUS Eastern Standard Time

More:
Senior Lecturer, Bacteriology job with UNIVERSITY OF MELBOURNE | 304525 - Times Higher Education

Immunology

Immunology Drugs Market worth $183.49 billion by 2030 – Exclusive Report by InsightAce Analytic – PR Newswire UK

JERSEY CITY, N.J., July 18, 2022 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the 'Global Immunology Drugs Market By Drug Class (Monoclonal antibodies, Fusion Proteins, Immunosuppressants, Polyclonal antibodies, and Other Drug classes), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others), Disease Indications (Rheumatoid Arthritis, Psoriatic Arthritis, Plaque Psoriasis, Ankylosing Spondylitis, Inflammatory Bowel Disease, and Other disease Indication)) - Trends, Industry Competition Analysis, Revenue and Forecast To 2030.'

According to the latest research by InsightAce Analytic, global immunology drugs market is valued at US$ 88.85 Billion in 2021, and it is expected to reach US$ 183.49 Billion by 2030, with a CAGR of 8.7% during the forecast period of 2022-2030.

Request for Sample Pages: https://www.insightaceanalytic.com/request-sample/1328

Immunology Drugs are substances and drugs that modify the immunological response by stimulating or suppressing the immune system. They are used to treat or prevent a variety of autoimmune and immunological conditions, as well as to combat infections. Increased awareness of immunological illnesses in both emerging and developed nations and the growing prevalence of immunological disorders induced by environmental factors are significant drivers propelling the expansion of the global market.

There is a sizable patient population with autoimmune illnesses due to a variety of environmental factors, such as infections, stress, dietary components, gut dysbiosis, and exposure to hazardous substances. With the high demand for these medications globally, market participants are actively investing in their research and development. Additionally, during the projected period, increased autoimmune illness awareness in both developed and developing countries and prospective pipeline candidates are predicted to propel market expansion. The Immunology Drugs drug market is anticipated to rise as a result of patients with poor prognoses. Trial data shows that therapeutic effects last for an extended period even after the tumor has been reduced after the immune system has been primed to attack cancer Immunology Drugs.

Despite the fact that immunological illnesses are growing more prevalent in significant regions, the market's expansion is constrained over the projected period by a number of factors. High costs and adverse side effects are two factors expected to limit the market. Biologics are expensive due in part to the high cost of manufacturing facilities and the substantial expenditure in research and development needed to get biologics through the FDA approval and clinical trial procedures.

The market for Immunology Drugs is anticipated to be dominated by North America. Due to its well-developed healthcare infrastructure, higher prevalence of chronic diseases, and comparatively higher diagnosis and treatment rates, the United States now dominates the global market. Increasing patient demand for treatment options and increased public awareness are expected to boost demand throughout the projected period. Prominent players in the immunology drugs market are Eli Lilly Company, AbbVie Inc, F.Hoffmann-La roche Ltd, Amgen Inc, Pfizer, Novartis, Astellas, Alector, ImmuNext, Merck sharp & Dohme Corp., UCB SA, and other prominent players.

Key Developments In The Market:

Curious about this latest version of the report? Enquiry Before Buying athttps://www.insightaceanalytic.com/enquiry-before-buying/1328

Global Immunology Drugs Market, by by Drug Class, 2022-2030 (Value US$ Bn)

Global Immunology Drugs Market, by Distribution Channel, 2022-2030 (Value US$ Bn)

Global Immunology Drugs Market, by Disease Indications, 2022-2030 (Value US$ Bn)

Rheumatoid Arthritis

Global Immunology Drugs Market, by Region, 2022-2030 (Value US$ Bn)

North America Immunology Drugs Market, by Country, 2022-2030 (Value US$ Bn)

Europe Immunology Drugs Market, by Country, 2022-2030 (Value US$ Bn)

Asia Pacific Immunology Drugs Market, by Country, 2022-2030 (Value US$ Bn)

Latin America Immunology Drugs Market, by Country, 2022-2030 (Value US$ Bn)

Middle East & Africa Immunology Drugs Market, by Country, 2022-2030 (Value US$ Bn)

Why should buy this report:

For More Customization at https://www.insightaceanalytic.com/customisation/1328

Other Related Reports Published by InsightAce Analytic:

Global Neuropsychiatric Drugs Market

Global Neuroimmunology Drugs Market

Global Neurodegenerative Disease Market

Global Preclinical Oncology Models Market

Global Immuno-Oncology Cell Therapy Market

About Us:

InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact Us:InsightAce Analytic Pvt. Ltd.Tel.: +1 551 226 6109Email:info@insightaceanalytic.comSite Visit:www.insightaceanalytic.comFollow Us on LinkedIn @bit.ly/2tBXsgSFollow Us OnFacebook@bit.ly/2H9jnDZ

Logo: https://mma.prnewswire.com/media/1729637/InsightAce_Analytic_Logo.jpg

SOURCE InsightAce Analytic Pvt. Ltd.

Originally posted here:
Immunology Drugs Market worth $183.49 billion by 2030 - Exclusive Report by InsightAce Analytic - PR Newswire UK

Immunology

Assistant Professor in Molecular Biology / Immunology job with THE HONG KONG POLYTECHNIC UNIVERSITY | 302110 – Times Higher Education

The Hong Kong Polytechnic University (PolyU) is a government-funded tertiary institution in Hong Kong. It offers programmes at various levels including Doctorate, Masters, and Bachelors degrees. It has a full-time academic staff strength of around 1,200. The total annual consolidated expenditure budget of the University is in excess of HK$7.6 billion.

DEPARTMENT OF APPLIED BIOLOGY AND CHEMICAL TECHNOLOGY

The Department of Applied Biology and Chemical Technology (ABCT) is a multi-disciplinary department in The Hong Kong Polytechnic University (PolyU) with diversified specialties in biology, biotechnology, chemistry, biochemistry, nutrition and food science. The Departments research focus is in the interdisciplinary areas of chemistry, biology and food science. There are about 60 faculty members in the Department. Please visit the website at http://www.polyu.edu.hk/abct for more information about the Department.

Assistant Professor in Molecular Biology / Immunology (Ref. 220721011)

The appointee will be required to

(a) conduct independent research, develop interdisciplinary collaborations and demonstrate research accomplishments of originality and depth;

(b) actively pursue external research grants, such as General Research Fund, as Principal Investigator or Co-Investigator;

(c) provide quality teaching at undergraduate and/or postgraduate levels; and

(d) contribute to departmental service.

Applicants should

(a) have a doctoral degree in related disciplines with at least three years of relevant postdoctoral experience;

(b) have potential to become a leader in one or several of the research fields of biotechnology, biochemistry or drug and probiotics development, especially those related to immunology, neuroinflammation, chronic metabolic diseases and inflammatory bowel disease, etc.;

(c) be able to conduct lectures, practical sessions, and tutorials at postgraduate and undergraduate levels in Molecular Biology / Biochemistry / Protein Structure / Immunology (Basic / Clinical), Clinical Microbiology (Basic / Clinical), Immunotechnology and Virology;

(d) be highly proficient in written and spoken English; and

(e) be able to demonstrate evidence of possession of effective classroom teaching skills.

Conditions of Service

A highly competitive remuneration package will be offered. Initial appointment will be on a fixed-term gratuity-bearing contract. Re-engagement thereafter is subject to mutual agreement.

Application

Please submit an application through PolyUs career website (https://jobs.polyu.edu.hk/academic).Consideration of applications will commence on 4 August 2022 until the position is filled. The Universitys Personal Information Collection Statement for recruitment can be found at https://www.polyu.edu.hk/hro/careers/pics_for_recruitment/.

PolyU is an equal opportunity employer committed to diversity and inclusivity. All qualified applicants will receive consideration for employment without regard to gender, ethnicity, nationality, family status or physical or mental disabilities.

Link:
Assistant Professor in Molecular Biology / Immunology job with THE HONG KONG POLYTECHNIC UNIVERSITY | 302110 - Times Higher Education

Immunology

Maintenance of immunity to COVID-19 after infection or vaccination – EurekAlert

image:Topics cover both human and animal viral immunology, exploring viral-based immunological diseases, pathogenic mechanisms, and virus-associated tumor and cancer immunology. view more

Credit: Mary Ann Liebert, Inc., publishers

A new study examined the maintenance of memory B cell responses to SARS-CoV-2, the virus that causes COVID-19, after recovery from natural infection or post-vaccination. The study is published in the peer-reviewed journal Viral Immunology. Click here to read the article now.

The study, coauthored by David Fear, from Kings College London, and colleagues, showed that among those recovered from natural infection, COVID-19 serologically-positive donors had strong antigen-specific memory B cell-associated responses. Post-vaccination, donors showed robust serological antigen-specific antibody responses against spike protein that waned over time. Memory B cell-associated responses against spike protein were also observed but showed less waning over time.

This study is of particular relevance at the moment, because with millions vaccinated, previously infected, or both, studies such as this one may tell us how long we might expect the immunity to last, says Rodney S. Russell, PhD, Editor-in-Chief of Viral Immunology, from Memorial University of Newfoundland, St. Johns.

About the Journal

Viral Immunology is an authoritative peer-reviewed journal published ten times a year in print and online. Topics cover both human and animal viral immunology, exploring viral-based immunological diseases, pathogenic mechanisms, and virus-associated tumor and cancer immunology. The Journal includes original research papers, review articles, and commentaries covering the spectrum of laboratory and clinical research and exploring developments in vaccines and diagnostics targeting viral infections. Tables of content and a sample issue may be viewed on the Viral Immunology website.

About the Publisher

Mary Ann Liebert, Inc., publishers is known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industrys most widely read publication worldwide. A complete list of the firms more than 100 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.

Case study

People

SARS-CoV-2-specific memory B cell responses are maintained after recovery from natural infection and postvaccination

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Read more from the original source:
Maintenance of immunity to COVID-19 after infection or vaccination - EurekAlert

Immunology

Accelerating Transformational Research into Cell Transplantation for Patients with Type 1 Diabetes – UCSF

Loren and Mike Gordon. Image by Sonya Yruel

A personal investigation into the lifelong implications of his type 1 diabetes (T1D) culminated in a $7 million gift from Mike Gordon, co-founder of Meritech Capital Partners, and his wife, Loren, to help UCSF surmount a key impediment to treating the disease. The funds will support world-class stem cell biologists, immunologists, and bioengineers who are working to overcome significant barriers to beta-cell replacement therapy as an effective treatment for T1D.

Diagnosed when he was just 22 months old, Gordon went through a whole pancreas transplant at UCSF nearly 12 years ago. As a result, he has fewer complications from T1D but must take immunosuppressant drugs and endure the health risks that come with them for the rest of his life.

We wanted to give these researchers freedom to explore bold ideas.

Mike Gordon

Ive suffered a lot from this disease, Gordon said. People say, Its not that bad. Its a chronic condition. But you can fall apart.

Some 1.6 million people in the US have T1D, a disease that is often disabling and can become life-threatening. Diagnoses typically occur in childhood, but not always. The disease develops when the patients immune system attacks its own beta cells, which make insulin in the pancreas. The resulting lack of insulin leaves the body unable to absorb sugar from the bloodstream and convert it into energy, so sugar builds up in the blood. Patients are subject to a lifelong dependence on insulin and are at a higher risk for heart disease, blindness, kidney failure, and other chronic conditions, in addition to shortened average life expectancy.

Beta cell-replacement therapy has shown enormous promise for T1D patients. Beta cells make up 50%-70% of the cells in human pancreatic islets groups of cells in the pancreas that produce blood glucose-regulating hormones and they are the sole producers of insulin in the body. However, replacement beta cells dont live long, and the immune system often rejects the ones that do survive. To prevent the immune system from attacking the replacement cells, immunosuppressants are necessary, but they can be toxic and leave patients vulnerable to malignancies and other infections. UCSF scientists are poised to find solutions to these challenges.

So often the NIH provides funds for low-risk projects where outcomes are more predictable, Gordon said. We didnt want that; we wanted to give these researchers freedom to explore bold ideas.

The research team will use the Gordons investment to help answer two big questions: How can they prolong the survival of replacement beta cells after transplantation? And, can the need for patients to take immunosuppressive drugs be eliminated? The answers to these questions will be a game-changer for patients around the world.

Four interdisciplinary investigators will lead the research:

Julie B. Sneddon, PhDAssistant professor in the UCSF Diabetes Center, the UCSF Broad Center of Regeneration Medicine and Stem Cell Research, and the UCSF Department of Cell and Tissue Biology

Currently, islet-cell replacement relies on obtaining pancreatic tissue from deceased human donors. Thanks to groundbreaking advances during the last decade, beta cells can now be laboratory-generated from pluripotent stem cells, which means supplies, in theory, are unlimited. This creates an opportunity to engineer the stem cell-derived beta cells in ways that support their survival and help them avoid attack by the immune system.

We used to say we were 10 years away from a cure for T1D. We still might be. But if you look at the advances in cell biology and immunology, we have the road map now, Parent said.

Over the past five years, Drs. Parent, Tang, Sneddon, and Desai have co-advised trainees, joined forces on numerous projects, and published papers together. Their labs combine the fresh perspectives and innovation of junior faculty members with the expertise and experience of senior faculty members. The groups collective knowledge, unique understanding, and productive ongoing collaborations position them as an effective group to take on this challenge.

Insulin was first used to successfully treat a patient with type 1 diabetes a century ago, but it wasnt until 1980 that two Minnesota surgeons demonstrated successful intraportal islet transplantation in 10 patients with surgically induced diabetes (in which the patients own islet cells, or autografts, were infused back into their bodies after islet isolation). Ultimately, three of those patients achieved insulin independence for one, nine, and 38 months, respectively. In the last decade, significant strides have been made in groundbreaking technologies such as immunotherapy, metabolomics, and genomics. UCSF has been at the forefront of these advances, especially in immunology, with the Bakar ImmunoX initiative driving collaborative science and the UCSF Helen Diller Family Comprehensive Cancer Center using immunotherapies to find cures for some cancer patients.

All this progress has positively impacted diabetes research. Mark Anderson, MD, PhD, the Robert B. Friend and Michelle M. Friend Professor of Diabetes Research and the new director of the UCSF Diabetes Center, is optimistic about this moment in time and what it means for our patients with T1D and other diseases.

These developments provide unique opportunities for physician-scientists to research the molecular causes of diseases like T1D and potentially replace damaged tissues and repair malfunctioning organs, Anderson said.

Anderson believes that UCSF is one of the few places in the world capable of assembling this type of collaborative team. We are so fortunate to have the Gordons support and shared vision to help us realize the potential of cell transplantation without immune suppression, which could completely change the lives of those affected by T1D.

Original post:
Accelerating Transformational Research into Cell Transplantation for Patients with Type 1 Diabetes - UCSF

Immunology

Elsevier partners with the Society for Mucosal Immunology to publish Mucosal Immunology – EurekAlert

image:Editor-in-Chief of Mucosal Immunology view more

Credit: Ben Marsland

Amsterdam, July 18, 2022 The Society for Mucosal Immunology (SMI), the preeminent international community of researchers working together to advance the field of mucosal immunology and improve health worldwide, and Elsevier, a global leader in research publishing and information analytics, are delighted to announce a new partnership to publish SMIs official journal, Mucosal Immunology. The journal will transition to gold open access, making articles immediately and permanently available for everyone to read, download, copy and distribute. It will be hosted on Elseviers leading online platform, ScienceDirect, beginning January 2023.

SMIs decision to partner with Elsevier furthers its ongoing mission to directly support research and education and foster communication and collaboration in the field of mucosal immunology. Transitioning its journal from its current subscription model to gold open access clearly reflects its commitment to make its content more easily accessible and drive innovation in the field.

SMI President Michael McGuckin, PhD, said: We welcome Elsevier as our new publisher and look forward to taking advantage of its publishing expertise and commitment to open science as we continue our journey to increase the visibility and influence of Mucosal Immunology together. It is clear from our early interactions with Elsevier staff and leadership that this will be a partnership in the truest sense of the word and enable us to build upon the journals high standards and further enhance its global prominence.

Since 1990, mucosal immunology has expanded from what many considered a niche discipline to one of the hottest areas in immunobiology today, underpinned by interactions with the microbiome and nervous system that have profound implications for health and disease. The journal fosters cross-fertilization between scientists, clinical researchers and industry professionals across a broad spectrum of specialties working on pathways of immunity and inflammation at barrier surfaces. They rely on Mucosal Immunology for the very latest robust, cutting-edge original research and reviews in basic, translational and clinical science.

The journal has earned a strong reputation for publishing papers based on the quality of the science, its rapid and rigorous peer review, and its contributions to advancing the field. This is demonstrated by its impressive 2021 Journal Impact Factor of 8.701* and a steadily increasing online and social media community.

Mucosal Immunologys eminent international editorial board under the continued leadership of Editor-in-Chief Ben Marsland, PhD, ensures that this high quality, peer-reviewed journal will continue to be an authoritative resource for the community it serves.

The editorial board and I are tremendously excited for the opportunity to partner with Elsevier to publish Mucosal Immunology, said Professor. Marsland. I have every confidence that support from the Elsevier team will foster even greater success in our ongoing efforts to publish novel, transformative, and clinically relevant science. On behalf of Mucosal Immunologys editors, editorial staff, reviewers, and authors, I want to welcome our new partner.

Elsevier is firmly committed to the continuity of the journals rigorous editorial process and accessibility of content, and further solidifying Mucosal Immunologys reputation.

We are delighted that SMI has selected Elsevier as its publishing partner. By combining their expertise with Elseviers industry-leading resources for authors, editors, peer reviewers and readers, we will ensure the best possible support for SMIs mission and community. By working together, we can achieve a more inclusive, collaborative and transparent world of research, stated Louise Curtis, Senior Vice President, Life Sciences & Social Sciences, at Elsevier.

Mucosal Immunology is a great asset to the Elsevier immunology journal portfolio, and we look forward to helping the society and their journal navigate a successful transition to full open access status, added Jenny Henzen, Elseviers Publisher for Immunology.

*Journal Citation Reports, Clarivate, 2022

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Read more here:
Elsevier partners with the Society for Mucosal Immunology to publish Mucosal Immunology - EurekAlert